Efficiency of a subunit vaccine consisting of GP130 micelles in protection of rhesus monkeys against challenge with SIVmac251/32H. NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Efficiency of a subunit vaccine consisting of GP130 micelles in protection of rhesus monkeys against challenge with SIVmac251/32H.

Symp Nonhum Primate Models AIDS. 1992 Nov 17-20;10:abstract no. 122. Unique Identifier : AIDSLINE PRIM10/93200962
Luke W; Voss G; Dittmer U; Coulibaly C; Stahl-Hennig C; Petry H; Hunsmann G; German Primate Center, Gottingen.

Abstract: Three rhesus monkeys were immunized four times four weeks apart with a total of 400 g of gp130 micelles per animal, mixed with KLH and emulsified in incomplete Freund's adjuvant. All immunized animals have developed antibody titers of about 10(5) against gp130. Neutralizing and CD4-binding inhibiting antibodies could also be found. The proliferative T-cell response as well as cytotoxic T-cell activity were measured. After an immunization pause of two month, the animals will be immunized again and challenged two weeks thereafter along with two naive control animals with 10 MID50 of SIVmac251/32H. The results after challenge will be presented and discussed.
Keywords: Animal Antibody Formation Freund's Adjuvant Lymphocyte Transformation Macaca mulatta Micelles Simian Acquired Immunodeficiency Syndrome/*IMMUNOLOGY/PREVENTION & CONTROL SIV/*IMMUNOLOGY T-Lymphocytes/DRUG EFFECTS/*IMMUNOLOGY T-Lymphocytes, Cytotoxic/IMMUNOLOGY Vaccines, Synthetic/*PHARMACOLOGY Viral Envelope Proteins/IMMUNOLOGY Viral Vaccines/*PHARMACOLOGY ABSTRACTKWDanimalantibodyformationfreund'sadjuvantlymphocytetransformationmacacamulattamicellessimianacquiredimmunodeficiencysyndrome/KWDimmunology/prevention&controlsiv/KWDimmunologyt-lymphocytes/drugeffects/KWDimmunologyt-lymphocytes,cytotoxic/immunologyvaccines,synthetic/KWDpharmacologyviralenvelopeproteins/immunologyviralvaccines/KWDpharmacologyabstract
930630
M9361058

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .